Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical diclofenac added to intravitreal bevacizumab for diabetic macular edema
IRCT20220423054625N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of diclofenac and bevacizumab in diabetic macular edema (DME) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Macula central thickness and Visual acuity. Started Dec 2023; status: completed.
02
Drugs
diclofenacbevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20220423054625N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220423054625N1.